Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: AVE1642
Drug: Velcade

First Posted Date: 2010-11-03

Last Posted Date: 2010-11-03

Lead Sponsor: Sanofi

Target Recruit Count: 26

Registration Number: NCT01233895

Locations: 🇫🇷
Sanofi-Aventis Investigational Site Number 250002, Lille, France
🇫🇷
Sanofi-Aventis Investigational Site Number 250003, Vandoeuvre Les Nancy, France
🇮🇹
Sanofi-Aventis Investigational Site Number 380001, Torino, Italy

and more 1 locations

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine

First Posted Date: 2010-10-21

Last Posted Date: 2013-08-12

Lead Sponsor: Sanofi

Target Recruit Count: 405

Registration Number: NCT01226043

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin glargine (HOE901)
Drug: NPH insulin

First Posted Date: 2010-10-18

Last Posted Date: 2014-04-01

Lead Sponsor: Sanofi

Target Recruit Count: 162

Registration Number: NCT01223131

Locations: 🇨🇳
Investigational Site Number 156006, Beijing, China
🇨🇳
Investigational Site Number 156001, Beijing, China
🇨🇳
Investigational Site Number 156004, Hangzhou, China

and more 7 locations

Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia

Completed

Conditions: Dengue Fever
Fever

First Posted Date: 2010-10-11

Last Posted Date: 2018-01-16

Lead Sponsor: Sanofi

Target Recruit Count: 1500

Registration Number: NCT01218906

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Sarilumab
Drug: Golimumab
Drug: Folic/folinic acid
Drug: methotrexate (MTX)

First Posted Date: 2010-10-08

Last Posted Date: 2017-09-01

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT01217814

Locations: 🇲🇽
Investigational Site Number 484008, Durango, Mexico
🇨🇴
Investigational Site Number 170004, Barranquilla, Colombia
🇨🇴
Investigational Site Number 170005, Barranquilla, Colombia

and more 11 locations

Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Pertussis
Poliomyelitis
Haemophilus Influenzae Type B

First Posted Date: 2010-10-05

Last Posted Date: 2012-04-17

Lead Sponsor: Sanofi

Target Recruit Count: 370

Registration Number: NCT01214889

Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: DRONEDARONE (SR33589)
Drug: placebo

First Posted Date: 2010-10-04

Last Posted Date: 2013-10-16

Lead Sponsor: Sanofi

Target Recruit Count: 181

Registration Number: NCT01213368

Locations: 🇯🇵
Investigational Site Number 392008, Kawasaki-Shi, Japan
🇯🇵
Investigational Site Number 392019, Nagasaki-Shi, Japan
🇯🇵
Investigational Site Number 392010, Osaka-Shi, Japan

and more 22 locations

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advance Solid Tumors

Interventions: Drug: Iniparib (SAR240550 - BSI-201)
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2010-10-04

Last Posted Date: 2013-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT01213381

Locations: 🇯🇵
Sanofi-Aventis Investigational Site Number 392001, Kobe-Shi, Japan
🇯🇵
Sanofi-Aventis Investigational Site Number 392002, Matsuyama-Shi, Japan

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: INSULIN GLARGINE
Drug: Insulin aspart
Drug: INSULIN GLULISINE

First Posted Date: 2010-10-01

Last Posted Date: 2013-07-08

Lead Sponsor: Sanofi

Target Recruit Count: 161

Registration Number: NCT01212913

Locations: 🇰🇷
Administrative Office, Seoul, Korea, Republic of

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer Female

Interventions: Drug: Iniparib (SAR2405550 -BSI-201)
Drug: paclitaxel

First Posted Date: 2010-09-17

Last Posted Date: 2017-03-22

Lead Sponsor: Sanofi

Target Recruit Count: 141

Registration Number: NCT01204125

Locations: 🇫🇷
Investigational Site Number 250002, Toulouse, France
🇫🇷
Investigational Site Number 250001, Besancon Cedex, France
🇫🇷
Investigational Site Number 250004, Bordeaux, France

and more 22 locations

Home Terms & Conditions Privacy Policy